Cardima Surgical Ablation System Featured in Podium Presentation by Dr. Li Poa at ACTS 2009 Meeting.Company to Exhibit Surgical Ablation System Products at ACTS 2009 and American Association of Thoracic Surgeons Meetings FREMONT, Calif. -- Cardima, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : CADM CADM Core Architecture Data Model (DoD) CADM Computer-Aided Design and Manufacturing CADM C4ISR Core Architecture Data Model CADM Configuration & Data Management CADM Clean Air Device Manufacturers Association ) today announced that surgical ablation thought leader, Dr. Li Poa, will present data from his experience with the Cardima Surgical Ablation System at the ACTS 2009: Advanced Cardiac Techniques in Surgery Meeting on May 7, 2009. Cardima also will showcase its products and technologies at the ACTS 2009 meeting being held on May 6-7, 2009 in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , as well as at the 89th Annual Meeting of the American Association for Thoracic Surgery Thoracic Surgery Definition Thoracic surgery is the repair of organs located in the thorax, or chest. The thoracic cavity lies between the neck and the diaphragm, and contains the heart and lungs (cardiopulmonary system), the esophagus, trachea, pleura, (AATS AATS American Association for Thoracic Surgery AATS Ames Airborne Tracking Sunphotometer AATS Alternate Aircraft Takeoff System AATS Anti Aircraft Target System AATS Aircrew/Aircraft Tasking System AATS Audit Action Tracking System ) May 9-13, 2009 in Boston. Cardima executives will attend both conferences to meet with industry executives and interested investors. Dr. Poa, FACS FACS Fellow of the American College of Surgeons. FACS abbr. Fellow of the American College of Surgeons FACS fluorescence-activated cell sorter. , Chief of Cardiothoracic Surgery and Cardiac Surgery Program Director at Stamford Hospital, Connecticut, and faculty member of Columbia University, New York, heads the Cardima Center of Excellence and Training Program at Stamford Hospital. "I look forward to presenting data collected from procedures using the Cardima Surgical Ablation System in my presentation, 'Keys to Surgical Ablation: Stamford Experience with the Cardima System,'" Dr. Poa said. "The Cardima system is capable of creating a fairly complete, complex lesion set during both open- and closed-chest procedures. It can reliably and reproducibly establish both entrance and exit conduction block, which is an important attribute for achieving effective, long-term ablation results. Additionally, the system is capable of creating continuous transmural transmural /trans·mu·ral/ (trans-mu´ral) through the wall of an organ; extending through or affecting the entire thickness of the wall of an organ or cavity. trans·mu·ral adj. lesions without gaps, and can be easily manipulated to create all the necessary lesions for a full surgical procedure." "We are delighted that Dr. Poa, a recognized world-leading authority on surgical ablation, will share his experience with the Cardima Surgical Ablation System at this international gathering of cardiothoracic cardiothoracic /car·dio·tho·rac·ic/ (-thah-ras´ik) pertaining to the heart and the thorax. car·di·o·tho·rac·ic n. Of or relating to the heart and the chest. surgeons and thought-leaders," said Cardima's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Robert Cheney. "Creating awareness about the advanced features of our Surgical Ablation System at key meetings such as the ACTS 2009 and AATS, along with developing Centers for Excellence and broadening distribution are integral parts of our strategy to support product adoption." Cardima Product Exhibition Information: * At the ACTS 2009 meeting, May 6-7, Cardima products and technology will be displayed at the Exhibit Hall at the Equitable Center. The ACTS 2009 meeting features the latest surgical and interventional therapies for heart valve and coronary artery diseases, chronic atrial fibrillation atrial fibrillation Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. and diseases of the aorta. * At AATS, May 9-13, Cardima products will be showcased at the Hynes Convention Center The John B. Hynes Veterans Memorial Convention Center located in Boston's Back Bay has 193,000 square feet (0 m) of exhibit space and can accommodate up to four concurrent events. at exhibition booth #608. The AATS annual meeting brings together the world's leading scientists in thoracic and cardiovascular surgery to discuss their latest clinical and research efforts. For physicians attending ACTS 2009 or AATS interested in learning more about Cardima's Surgical Ablation Program, please contact Anita Elliot via email at aelliot@cardima.com. About Cardima Surgical Ablation System The Surgical Ablation System uses Cardima's patented technology for the ablation of cardiac tissue. The System incorporates a microcatheter-based surgical probe coupled with Cardima's INTELLITEMP([R]), a radiofrequency energy management device. The probe incorporates irrigation irrigation, in agriculture, artificial watering of the land. Although used chiefly in regions with annual rainfall of less than 20 in. (51 cm), it is also used in wetter areas to grow certain crops, e.g., rice. , suction and illumination, which aid in placement and lesion depth. The Cardima Surgical Ablation System is able to create deep, long, linear and transmural cardiac lesions without gaps. The small, flexible design offers sole port-hole access, potentially decreasing procedure time, patient hospital stay and discomfort. About Cardima Cardima, Inc. has developed the PATHFINDER([R]), TRACER[TM] and REVELATION([R]) Series of diagnostic catheters, the VUEPORT([R])and NAVIPORT([R]) Series of guiding catheters, the INTELLITEMP([R]) Energy Management Device and the Surgical Ablation System. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) 510(k) clearance. The REVELATION([R]) Series of ablation catheters with the INTELLITEMP([R]) EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe. PATHFINDER([R]), TRACER[TM], VUEPORT([R]), NAVIPORT([R]), REVELATION([R]) and INTELLITEMP([R]) are registered trademarks of Cardima, Inc. Forward-Looking Statements This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion